Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
Baudry E, Naoun N, Auclin E, Saldana C, Barthelemy P, Geoffrois L, Thibault C, de Vries-Brilland M, Borchiellini D, Maillet D, Hirsch L, Vauchier C, Carril-Ajuria L, Colomba E, Bernard-Tessier A, Escudier B, Flippot R, Albigès L. Baudry E, et al. Among authors: escudier b. Eur J Cancer. 2023 Nov;193:113292. doi: 10.1016/j.ejca.2023.113292. Epub 2023 Aug 18. Eur J Cancer. 2023. PMID: 37717282
Sequential therapy in renal cell carcinoma.
Escudier B, Goupil MG, Massard C, Fizazi K. Escudier B, et al. Cancer. 2009 May 15;115(10 Suppl):2321-6. doi: 10.1002/cncr.24241. Cancer. 2009. PMID: 19402067 Free article. Review.
Sunitinib rechallenge in metastatic renal cell carcinoma patients.
Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, Escudier B, Rini BI. Zama IN, et al. Among authors: escudier b. Cancer. 2010 Dec 1;116(23):5400-6. doi: 10.1002/cncr.25583. Epub 2010 Nov 2. Cancer. 2010. PMID: 21105118 Free article.
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B. Négrier S, et al. Among authors: escudier b. Lancet Oncol. 2011 Jul;12(7):673-80. doi: 10.1016/S1470-2045(11)70124-3. Epub 2011 Jun 12. Lancet Oncol. 2011. PMID: 21664867 Clinical Trial.
552 results